Total Payments
$151,206
2024 Payments
$21,267
Companies
18
Transactions
337
Medicare Patients
577
Medicare Billing
$96,949
Payment Breakdown by Category
Consulting$65,752 (43.5%)
Travel$56,324 (37.2%)
Other$14,100 (9.3%)
Food & Beverage$13,768 (9.1%)
Research$1,212 (0.8%)
Education$49.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $65,752 | 21 | 43.5% |
| Travel and Lodging | $56,324 | 86 | 37.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,100 | 4 | 9.3% |
| Food and Beverage | $13,768 | 199 | 9.1% |
| Unspecified | $1,212 | 8 | 0.8% |
| Education | $49.81 | 19 | 0.0% |
Payments by Type
General
$149,994
329 transactions
Research
$1,212
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $48,888 | 129 | $0 (2024) |
| Actelion Pharmaceuticals, Ltd | $31,194 | 21 | $0 (2019) |
| United Therapeutics Corporation | $29,795 | 88 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $15,920 | 31 | $0 (2022) |
| Merck Sharp & Dohme LLC | $14,434 | 26 | $0 (2024) |
| Gilead Sciences, Inc. | $6,332 | 11 | $0 (2018) |
| Abbott Laboratories | $1,440 | 4 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,212 | 8 | $0 (2018) |
| Sandoz Inc. | $530.25 | 8 | $0 (2023) |
| Amgen Inc. | $454.13 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,267 | 40 | Actelion Pharmaceuticals US, Inc. ($13,697) |
| 2023 | $14,712 | 47 | Merck Sharp & Dohme LLC ($6,912) |
| 2022 | $19,543 | 49 | Bayer HealthCare Pharmaceuticals Inc. ($11,112) |
| 2021 | $1,317 | 12 | United Therapeutics Corporation ($465.87) |
| 2020 | $1,981 | 5 | United Therapeutics Corporation ($1,981) |
| 2019 | $31,677 | 38 | United Therapeutics Corporation ($15,533) |
| 2018 | $26,088 | 49 | Actelion Pharmaceuticals, Ltd ($16,073) |
| 2017 | $34,620 | 97 | Actelion Pharmaceuticals US, Inc. ($12,432) |
All Payment Transactions
337 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | United Therapeutics Corporation | REMODULIN (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,490.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $9.72 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $692.16 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $64.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $51.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Cardiology | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $221.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $220.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/30/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | Cash or cash equivalent | $100.56 | General |
| Category: Cardiology | ||||||
| 10/05/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $89.56 | General |
| Category: Cardiology | ||||||
| 10/05/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $32.57 | General |
| Category: Cardiology | ||||||
| 09/30/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $516.22 | General |
| Category: Cardiology | ||||||
| 09/30/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $449.99 | General |
| Category: Cardiology | ||||||
| 09/04/2024 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 Marigen | Food and Beverage | Cash or cash equivalent | $129.90 | General |
| Category: Wound Care | ||||||
| 08/26/2024 | United Therapeutics Corporation | TYVASO (Drug), REMODULIN, ORENITRAM | Food and Beverage | In-kind items and services | $85.77 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 07/01/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $105.56 | General |
| Category: Cardiology | ||||||
| 06/29/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $44.06 | General |
| 06/28/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 06/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Cardiology | ||||||
| 05/24/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | Cash or cash equivalent | $78.76 | General |
| Category: Cardiology | ||||||
| 05/24/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | Cash or cash equivalent | $65.00 | General |
| Category: Cardiology | ||||||
| 05/21/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABIL | GlaxoSmithKline, LLC. | $1,212 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 186 | 341 | $248,397 | $39,292 |
| 2022 | 6 | 151 | 250 | $148,206 | $22,717 |
| 2021 | 6 | 139 | 254 | $156,289 | $25,952 |
| 2020 | 6 | 101 | 175 | $32,196 | $8,988 |
Total Patients
577
Total Services
1,020
Medicare Billing
$96,949
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 154 | $84,854 | $16,309 | 19.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 59 | 77 | $59,521 | $9,222 | 15.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 31 | $47,895 | $5,840 | 12.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $30,380 | $3,989 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 23 | 24 | $13,848 | $2,090 | 15.1% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 13 | 13 | $9,659 | $1,447 | 15.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 11 | 14 | $2,240 | $394.32 | 17.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 93 | $51,243 | $8,528 | 16.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 41 | 47 | $36,331 | $5,576 | 15.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 23 | 23 | $24,955 | $3,655 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 26 | 34 | $19,618 | $2,646 | 13.5% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2022 | 12 | 13 | $9,659 | $1,243 | 12.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 18 | 40 | $6,400 | $1,069 | 16.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 121 | $65,992 | $11,295 | 17.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 38 | 46 | $35,558 | $6,136 | 17.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $26,040 | $4,035 | 15.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 26 | $15,002 | $2,364 | 15.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 11 | 11 | $9,537 | $1,360 | 14.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 15 | 26 | $4,160 | $762.00 | 18.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 36 | 81 | $14,580 | $4,729 | 32.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 17 | 40 | $4,000 | $1,277 | 31.9% |
| 93451 | Insertion of catheter for diagnostic evaluation of right heart structures | Facility | 2020 | 13 | 13 | $8,229 | $1,157 | 14.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 13 | $2,454 | $661.27 | 26.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 12 | 15 | $1,120 | $624.37 | 55.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 12 | 13 | $1,813 | $540.18 | 29.8% |
About Dr. Marc Simon, MD
Dr. Marc Simon, MD is a Specialist healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346215449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Simon, MD has received a total of $151,206 in payments from pharmaceutical and medical device companies, with $21,267 received in 2024. These payments were reported across 337 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($65,752).
As a Medicare-enrolled provider, Simon has provided services to 577 Medicare beneficiaries, totaling 1,020 services with total Medicare billing of $96,949. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease
- Location San Francisco, CA
- Active Since 02/22/2006
- Last Updated 10/14/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1346215449
Products in Payments
- UPTRAVI (Drug) $16,427
- Adempas (Drug) $15,797
- NONE (Drug) $15,122
- OPSUMIT (Drug) $11,477
- Letairis (Drug) $6,216
- TYVASO (Drug) $5,396
- WINREVAIR (Biological) $1,284
- CardioMEMS HF System (Device) $1,149
- ORENITRAM (Drug) $1,064
- TREPROSTINIL (Drug) $530.25
- Optimizer Smart System (Device) $440.30
- REMODULIN (Drug) $278.34
- CARDIOMEMS (Device) $177.66
- MITRIS RESILIA Mitral Valve (Device) $175.25
- OPSUMIT MACITENTAN (Drug) $152.37
- BOSENTAN (Drug) $150.91
- Kerecis Omega3 SurgiClose (Device) $129.90
- 2ND GEN CENTRIMAG PRIMARY CONSOLE (Device) $113.69
- ENTRESTO (Drug) $22.86
- Veltassa (Drug) $22.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in San Francisco
Dr. Ari Baron, M.d, M.D
Specialist — Payments: $930,952
Specialist $930,952
Dr. Jeffrey Wolf, M.d, M.D
Specialist — Payments: $458,581
Specialist $458,581
Dr. Bruce Mccormack, Md, MD
Specialist — Payments: $140,445
Specialist $140,445
Dr. Christopher Pilcher, M.d, M.D
Specialist — Payments: $110,726
Specialist $110,726
Dr. Bertrand Tuan, M.d, M.D
Specialist — Payments: $96,251
Specialist $96,251
Kenneth Light, M.d, M.D
Specialist — Payments: $88,269
Specialist $88,269